UnknownPhase 3NCT04018365

A Study of Empagliflozin in Patients With Refractory Diabetes Mellitus With Insulin Resistance

Studying NON RARE IN EUROPE: Metabolic syndrome

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Kobe University
Principal Investigator
Wataru Ogawa
Kobe University Hospital
Intervention
Empagliflozin Tablets(drug)
Enrollment
8 enrolled
Eligibility
20 years · All sexes
Timeline
20192021

Study locations (5)

Collaborators

Boehringer Ingelheim

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04018365 on ClinicalTrials.gov

Other trials for NON RARE IN EUROPE: Metabolic syndrome

Additional recruiting or active studies for the same condition.

See all trials for NON RARE IN EUROPE: Metabolic syndrome

← Back to all trials